Back to results
US 2025/0375444 A1Published application
Method of treating alzheimer’s disease
AssigneeAmyriad Pharma, Inc.
InventorSharon L. ROGERS
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to the treatment of Alzheimer's disease by administering 1′,3′-dihydro-2H-spiro[imidazo[1,2α]pyridine-3,2′-inden]-2-one orally at a daily dose of 180 mg as a single active agent or co-administered with donepezil hydrochloride and/or memantine hydrochloride.
Claims20
-66. (canceled)
A method of treating Alzheimer's Disease or dementia of the Alzheimer's type comprising co-administering orally to a human subject a daily dose of 180 mg of 1′,3′-dihydro-2H-spiro[imidazo-[1,2a]pyridine-3,2′-inden]-2-one (“AD101”) and one or more additional therapeutic agents.
Dependencies are inferred from the claim text.